VivoSim Labs
VIVSVivoSim Labs is a biotechnology services company specializing in the development and application of three-dimensional (3D) human tissue models for pharmaceutical testing.
Earnings
Next report
Nov 5, 2026 (in 2 months)Competitors
By market cap
By revenue growth
Profile
VivoSim Labs is a biotechnology services company specializing in the development and application of three-dimensional (3D) human tissue models for pharmaceutical testing. The company provides predictive toxicology screening and research services using proprietary bioprinting technology to help drug developers reduce the risk and cost of clinical failures. Their core value proposition lies in providing high-sensitivity, non-animal testing methodologies that mimic native human organ function.
A pioneer in 3D bioprinting with a foundational patent portfolio and best-in-class predictive sensitivity for liver toxicity.
FAQ
- What is VivoSim Labs's market cap?
- VivoSim Labs (VIVS) has a market capitalization of $3.9M and trades on NASDAQ.
- Who are VivoSim Labs's competitors?
- VivoSim Labs's key competitors include Charles River Laboratories, Champions Oncology, Inc., Revvity, Inc., and others. These companies compete in similar markets and product categories.
- Who does VivoSim Labs partner with?
- VivoSim Labs's notable partners include Eli Lilly and Company, BICO Group AB, University of Missouri-Columbia, and others.
- What subsidiaries does VivoSim Labs have?
- VivoSim Labs's subsidiaries include Organovo, Inc., VivoSim, Inc..
- Where is VivoSim Labs headquartered?
- VivoSim Labs is headquartered in United States of America and employs approximately 14 people. It has been publicly traded since 2011.